Evidence map›Paper›PMID 32883161›Full record

ArticleLupus2020

Factors associated with quality of life in cutaneous lupus erythematosus using the Revised Wilson and Cleary Model.

Motolani E Ogunsanya, Sung Kyung Cho, Andrew Hudson, Benjamin F Chong

Open access · greenAbstract readMulticenter StudyValidation Study
In one paragraph

Article in Lupus, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Lupus Erythematosus Quality of Life Questionnaire (LEQoL): Development and Psychometric Properties.International journal of environmental research and public health · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Motolani E OgunsanyaCollege of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.ORCID https://orcid.org/0000-0002-4005-0446
Sung Kyung ChoDepartment of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Andrew HudsonDepartment of Internal Medicine, Texas Health Presbyterian Hospital Dallas, Dallas, TX, USA.
Benjamin F ChongDepartment of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
The University of Texas Southwestern Medical Center · USTexas Health Dallas · USUniversity of Oklahoma Health Sciences Center · US

Funding

Tracking and Evaluation CoreU54GM104938 · NIGMS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI TIMOTHY M VANWAGONER · 2013 to 2026
$68.2M
Molecular Markers in Discoid Lupus ErythematousK23AR061441 · NIAMS · UT SOUTHWESTERN MEDICAL CENTER · PI CHONG, BENJAMIN FRANKLIN · 2012 to 2016
$653k
NIAMS NIH HHS K23 AR061441NIGMS NIH HHS U54 GM104938
6 · The paper itself

Abstract

objectivesThe purpose of this study was to characterize the impact of cutaneous lupus erythematosus (CLE) in adults and identify the clinical and non-clinical factors associated with quality of life (QoL), using the Revised Wilson and Cleary Model.

methods101 patients diagnosed with CLE were included in this cross-sectional study. QoL was measured with the Cutaneous Lupus Erythematosus Quality of Life (CLEQoL) scale and disease activity and damage with the Cutaneous Lupus Activity and Severity Index (CLASI). Patient demographics, clinical, and disease characteristics were also collected. Descriptive statistics were calculated, and multiple regression was employed to determine significant (p < 0.05) predictors of overall QoL. Data were analyzed using SPSS v24.

resultsThe overall regression QoL model was significantly different from zero, (F = 24.96; df = 14, 76; p = <0.001). Disease activity (β = 0.13), pain (β = 0.13), fatigue (β = 0.24), body image (β = 0.62), and side effects (β = -0.13) were significant predictors of overall QoL while controlling for other predictor variables. Patients who experienced higher levels of disease activity, fatigue severity, pain levels, and greater degree of body dissatisfaction had significantly poorer QoL. Fewer side effects experienced from CLE medications were significantly associated with higher QoL.

conclusionsStudy findings support the considerable burden associated with CLE. Several modifiable variables such as pain, fatigue, body image, and disease activity were associated with QoL. Therefore, interventions that incorporate these variables may reduce negative impacts on QoL life and improve health outcomes in CLE patients. Furthermore, given the chronic and recurring nature of the condition, strategies focused on improving QoL are needed for this vulnerable population.

Indexed as

Health Status IndicatorsModels, TheoreticalQuality of LifeAdultBody ImageCross-Sectional StudiesFatigueFemaleHealth StatusHumansLinear ModelsLupus Erythematosus, CutaneousMaleMiddle AgedMultivariate AnalysisPainclinical researchCutaneous lupusquality of lifeskin lupussubacute lupus erythematosus

Identifiers

PMID32883161
PMCPMC7641991
OpenAlexW3083010340

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.